Loading
Coherence Neuro is building implanted devices that read and stimulate electrical activity around brain tumours, with the aim of tracking and eventually treating cancer in real time. Its first study records brain signals during surgery for newly diagnosed glioma.
Coherence Neuro designs therapeutic neurotechnology for cancer: implantable read and write devices intended to track tumours through electrical biomarkers and treat them with electrical stimulation in a closed loop. Its flagship SOMA-1 is described as a minimally invasive, MRI-safe brain-computer interface implanted during existing neurosurgery to monitor and treat conditions such as gliomas. Its first-in-human study, sponsored by Coherence Neuro Australia Pty Limited, uses the CIPHER System, an electrocorticography probe on the brain surface for neural recording and stimulation, during surgery for newly diagnosed glioma at the Royal Melbourne Hospital (NCT07465796); the company announced in June 2026 that procedures had begun. In 2026 it announced USD 45 million from Founders Fund and The OpenAI Startup Fund, which it calls its Series A, with Lux Capital, 8VC, Timeless, Olive Capital and Ahren joining, and named a first chronic human trial in glioblastoma as a goal. Its first registered cancer trial, NCT07465796, was posted on ClinicalTrials.gov in March 2026.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Co-led by Founders Fund and The OpenAI Startup Fund; the article is headed 2026 and the website's article list calls it the Series A. | 2026 | $45M | coherenceneuro.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/